Home > Healthcare > Pharmaceuticals > Finished Drug Form > Opioid Use Disorder Market

Opioid Use Disorder Market Share

Report ID: GMI5838
Published Date: May 2023
Report Format: PDF

Download Free Sample

Opioid Use Disorder Market Share

The key market players include

Alkermes, Inc.
Indivior PLC
BioDelivery Sciences International, Inc.
Orexo US, Inc.
Titan Pharmaceuticals, Inc.
Omeros Corporation
Camurus
Hikma Pharmaceuticals PLC
AstraZeneca plc
Viatris Inc.

Furthermore, players in the market constantly opt for efficient strategies to bolster their brand value as well as promote the global market growth. For instance, in December 2020, Orexo AB entered into an exclusive agreement with Accord Healthcare Limited for the commercialization of ZUBSOLVE and NALOXE sublingual tablets in Europe.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for opioid use disorder amassed USD 2.8 billion in 2022 and is set to grow at a 10.6% CAGR from 2023 to 2032 owing to the rise in drug approvals for the treatment of opioid use disorder and increasing opioid addiction cases in developed counties.

The buprenorphine segment is estimated to register significant growth from 2023 to 2032 owing to the increasing use of buprenorphine as an effective option to improve the quality of life for patients undergoing addiction treatment.

The North America opioid use disorder (OUD) industry accounted for more than 49.3% of the global industry revenue in 2022 and is poised to depict robust growth driven by the increasing number of product launches for the treatment of opioid use disorder and a well-established opioid industry across the region.

The major players operating in the market are Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, and Viatris Inc.